The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Targeting the function of the HER2 oncogene in human cancer therapeutics
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 4×
“The antitumor activity of both mAb 4D5 and trastuzumab are almost entirely abolished in the loss-of-function FcRg / mice, while the antitumor activity of subtherapeutic doses of mAb 4D5 and trastuzumab are greatly enhanced in the gain-of-function FcRII / mouse model (Clynes et al., 2000).”
BackgroundInfluentialVogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 4×
“, 2005), increases plasma phosphatase and tensin homolog (PTEN) localization and activity in cells (Nagata et al., 2004; Longva et al., 2005), and its antiproliferative and antitumor effects are attenuated by HER2 oncogene in human cancer therapeutics”
BackgroundInfluentialTargeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Cited by
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
Nguyen, K.-S. H., Kobayashi, S., & Costa, D. B. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.039 · Cited by 437
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
Classification of HER2 Receptor Status in Breast Cancer Tissues by MALDI Imaging Mass Spectrometry
Rauser, S., Marquardt, C., Balluff, B., Deininger, S.-O., Albers, C., Belau, E., Hartmer, R., Suckau, D., Specht, K., Ebert, M. P., et al. (2010) · Journal of Proteome Research · doi:10.1021/pr901008d · Cited by 276
Targeting HER proteins in cancer therapy and the role of the non-target HER3
Hsieh, A. C., & Moasser, M. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603910 · Cited by 269
Self-citation
Metadata
- Authors
- Moasser, M. M.
- Venue
- Oncogene
- Published
- 2007-05-07
- Volume
- 26
- Issue
- 46
- Pages
- 6577-6592
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1988610380
- Cited by
- 190
- References
- 7
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the function of the HER2 oncogene in human cancer therapeutics. https://app.cochat.ai/papers/10.1038/sj.onc.1210478
- The paper
- Moasser, M. M. (2007). Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene. https://doi.org/10.1038/sj.onc.1210478
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
